Cellulitis: Clinical Trials

32 trials for Cellulitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 completed. 32 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 332Completed 32
Phase 23Completed 3

Follow Cellulitis: new trials by email Literature Review of Cellulitis trials Research Report on Cellulitis

Trials (filtered) newest first · largest first

All 32 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis
Candicort®, Nizoral®, Baycuten N® - Tinea
Phase 3CompletedAche Laboratorios Farmaceuticos S.A.1252019-06-112021-09-20
The Effects of Iontophoresis in Women With Gynoid Hidrolipodystrophy.
iontophoresis + caffeine - Caffeine, Cellulitis
Phase 2 / Phase 3CompletedUniversidade Norte do Paraná302018-06-142019-04-16
Cantharidin Application in Molluscum Patients-1
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102 - Molluscum Contagiosum
Phase 3CompletedVerrica Pharmaceuticals Inc.2662018-03-212022-01-11
Cantharidin Application in Molluscum Patients
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102 - Molluscum Contagiosum
Phase 3CompletedVerrica Pharmaceuticals Inc.2622018-02-142021-12-14
Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
sodium fusidate, linezolid - Acute Bacterial Skin and Skin Structure Infections
Phase 3CompletedArrevus Inc.7162015-11-012019-04-19
Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Dalbavancin, Dalbavancin-matching Placebo - Abscess, Wound Infection
Phase 3CompletedDurata Therapeutics Inc., an affiliate of Allergan plc6982014-04-182018-09-28
Evaluation of the Activity of a Pharmacological "Anticellulitis" Product vs. a Reference Product on the Market
ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream - Healthy
Phase 3CompletedDerming SRL222013-09-012014-07-21
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Delafloxacin, Vancomycin, Aztreonam - Skin and Subcutaneous Tissue Bacterial Infections
Phase 3CompletedMelinta Therapeutics, Inc.6602013-04-012017-09-27
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
Ceftaroline fosamil, Vancomycin, Aztreonam - Complicated Skin and Soft Tissue Infection
Phase 3CompletedPfizer8022012-05-012017-09-06
Evaluation of Novel Antimicrobial Hand Towels
Antimicrobial Hand Towel - Diarrheal Diseases, Acute Respiratory Infections
Phase 2 / Phase 3CompletedCenters for Disease Control and Prevention4492012-03-012015-07-31
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
IV Dalbavancin, Vancomycin/Linezolid - Abscess, Wound Infection
Phase 3CompletedDurata Therapeutics Inc., an affiliate of Allergan plc7392011-07-012014-02-12
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Dalbavancin, Vancomycin / Linezolid - Abscess, Wound Infection
Phase 3CompletedDurata Therapeutics Inc., an affiliate of Allergan plc5732011-03-012014-01-31
Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)
Single-Dose IV Oritavancin Diphosphate, IV Vancomycin, Placebo - Wound Infection, Abscess
Phase 3CompletedMelinta Therapeutics, Inc.9682010-12-012022-08-01
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
Single-Dose IV Oritavancin Diphosphate, IV Vancomycin - Wound Infection, Abscess
Phase 3CompletedMelinta Therapeutics, Inc.10192010-12-012021-05-05
Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections
Daptomycin, Vancomycin or Semi-Synthetic Penicillins (SSPs) - Infections
Phase 3CompletedNovartis Pharmaceuticals1202010-03-012012-07-13
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
Retpamulin Ointment, 1%, Linezolid - Skin Infections, Bacterial
Phase 3CompletedStiefel, a GSK Company4102009-04-012017-03-27
China Registration Study in Patients With Skin Infections
Daptomycin, Vancomycin - Skin Diseases, Infectious
Phase 3CompletedAstraZeneca2652008-09-012015-03-09
Incision and Drainage Versus Needle Aspiration in Soft Tissue Abscesses
Incision and Drainage, Ultrasound Guided Aspiration - Abscess, Cellulitis
Phase 3CompletedUniversity of Massachusetts, Worcester1012008-08-012010-03-12
Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)
Retapamulin Ointment, 1%, Placebo ointment - Skin Infections, Bacterial
Phase 3CompletedGlaxoSmithKline5082008-05-012016-11-23
Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses
bactrim, placebo - Abscesses
Phase 3Completed59th Medical Wing2122007-11-012010-03-09

Showing 20 of 32. Sign in to see all of them.

Narrower conditions

Abscess (10)  ·  Wound Infection (7)  ·  Bacterial Infections (6)  ·  Skin Diseases, Bacterial (6)  ·  Infections (5)  ·  Skin Diseases (5)  ·  Surgical Wound Infection (5)  ·  Staphylococcal Infections (3)  ·  Impetigo (2)  ·  Molluscum Contagiosum (2)  ·  Poxviridae Infections (2)  ·  Skin Diseases, Infectious (2)  ·  Skin Diseases, Viral (2)  ·  Soft Tissue Infections (2)

Broader conditions

Connective Tissue Diseases (32)  ·  Inflammation (32)  ·  Pathologic Processes (32)  ·  Pathological Conditions, Signs and Symptoms (32)  ·  Skin and Connective Tissue Diseases (32)  ·  Suppuration (32)  ·  Skin Diseases, Infectious (30)  ·  Infections (27)  ·  Bacterial Infections and Mycoses (12)  ·  Skin Diseases (9)  ·  Bacterial Infections (5)  ·  Gram-Positive Bacterial Infections (5)  ·  Postoperative Complications (5)  ·  DNA Virus Infections (2)  ·  Disease Attributes (2)

Interventions

Vancomycin (11)  ·  Aztreonam (5)  ·  Linezolid (4)  ·  Ceftaroline (3)  ·  dalbavancin (3)  ·  Daptomycin (2)  ·  Levofloxacin (2)  ·  Tigecycline (2)  ·  VP-102 (2)  ·  Caffeine (1)  ·  Calcium Dobesilate (1)  ·  Cefazolin (1)  ·  Chlorhexidine (1)  ·  Cilastatin, Imipenem Drug Combination (1)  ·  Clotrimazole (1)

Sponsors

Durata Therapeutics Inc., an affiliate of Allergan plc (3)  ·  Melinta Therapeutics, Inc. (3)  ·  Arpida AG (2)  ·  Forest Laboratories (2)  ·  GlaxoSmithKline (2)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2)  ·  Pfizer (2)  ·  Verrica Pharmaceuticals Inc. (2)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (2)  ·  59th Medical Wing (1)  ·  Ache Laboratorios Farmaceuticos S.A. (1)  ·  Arrevus Inc. (1)  ·  AstraZeneca (1)  ·  Centers for Disease Control and Prevention (1)  ·  Derming SRL (1)

Countries

United States (20)  ·  Russia (9)  ·  Ukraine (8)  ·  Brazil (7)  ·  Germany (7)  ·  Poland (6)  ·  South Africa (6)  ·  Argentina (5)  ·  Croatia (5)  ·  Latvia (5)  ·  Mexico (5)  ·  Romania (5)  ·  Canada (4)  ·  Chile (4)  ·  Peru (4)

Top investigators

G. Ralph Corey, MD (2)  ·  Lawrence Eichenfield, MD (2)  ·  Michael Dunne, MD (2)  ·  Adele Sparavigna, Doctor (1)  ·  David Melnick, MSD (1)  ·  Jared Spotkov, M.D. (1)  ·  Karen Atkin (1)  ·  Loren Miller, M.D., M.P.H. (1)  ·  Mark Wilcox, MD (1)  ·  Ralph Corey, MD (1)

Results publications

PMID 30597021, PMID 30716446, PMID 34741280, PMID 34905144, PMID 34922058, PMID 20695801, PMID 21115456, PMID 24897082, PMID 27370913, PMID 29358292, PMID 32965495, PMID 33599960, PMID 34976290, PMID 12145720, PMID 19036671, PMID 19220646, PMID 20346539, PMID 21115454, PMID 21115455, PMID 24010809, PMID 24439136, PMID 24897083, PMID 25294250, PMID 25396674, PMID 26611777, PMID 27585969, PMID 28630189, PMID 29029278, PMID 30349845, PMID 30380060, PMID 30797084, PMID 32607967

NIH funding

2009 (1)